TCRT Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Alaunos Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerTCRT

Market Cap7.0M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

Alaunos Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Indibulin in Metastatic Breast Cancer (Phase 1).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Indibulin	Metastatic Breast Cancer	n/a	Phase 1	Public pipeline row
ZIO-201	Advanced Cancer	n/a	Phase 1	Public pipeline row
darinaparsin	Lymphoma	n/a	Phase 1	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT00421135	Phase 1	COMPLETED	30	2007-10
NCT00591136	Phase 1	COMPLETED	47	2008-09
NCT01139359	Phase 1	WITHDRAWN	n/a	2011-06
NCT01113970	Phase 1 \| Phase 2	UNKNOWN	60	2013-05
NCT05124743	n/a	TERMINATED	19	2023-08-14

Scientific Context

literature_publication | SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.
literature_publication | A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
literature_publication | Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2(+) breast cancer: TBCRC049 phase 2 study results.
literature_publication | Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
literature_publication | MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer.

Want the full TCRT research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.